The tumor-targeting ability of anti-CD38-LNPs was also validated in a xenograft MM mouse model, where specific delivery of cytoskeleton-associated protein 5 (CKAP5) siRNA to bone marrow-residing and disseminated MM cells and improved therapeutic outcomes were achieved (Tarab-Ravski et al.2023). This evidence concerns the gene CKAP5 and Miyoshi myopathy.